Document:

<PAGE>

                                                                   EXHIBIT 10.13

                         MANAGEMENT SERVICES AGREEMENT

THIS MANAGEMENT SERVICES AGREEMENT is made as of the 30th day of November, 1999
by and between Lakaro Biopharmaceuticals, Inc., a Delaware corporation (the
"Sponsor") and B.R.T. Biopharmaceuticals Ltd. (the "Company") an Israeli company
having its registered offices at Sha'arei Ha'ir, 216 Jaffa Street, Jerusalem,
Israel.

WHEREAS the Sponsor is a biopharmaceutical company engaged in the research and
development of biopharmaceutical products for the world market (the "Business");
and

WHEREAS the Sponsor wishes to engage the services of its subsidiary, the
Company, to carry out the services more fully set forth below in connection with
the Business.

NOW, THEREFORE, the parties agree as follows:

1.   Services
     --------

The Company shall, in consultation with the Sponsor:

1.1  supervise and monitor the research and development conducted in Israel in
     connection with the Business;

1.2  advise the Sponsor with respect to the direction of the Sponsor's research
     and product development in connection with the Business; and

1.3  report to the Sponsor on the progress of the research and product
     development being conducted in Israel in connection with the Business; and

1.4  assist in the performance of marketing services on behalf of the Sponsor in
     connection with the Business and any products developed in the Business;

1.5  continue with research and development, which shall include without
     limitation, the conducting of clinical trials; and

1.6  engage the services of advisory firms, consultants, and professionals, as
     it deems necessary, in order to better perform the services enumerated
     above (the "Services") or other services in connection therewith.

2.   Payment
     -------

     In consideration for the Services, the Sponsor will pay the Company during
     the term of this Agreement, a monthly fee equal to the amount of 110% of
     expenses incurred (the "Fee"), to be adjusted annually between the Sponsor
     and the Company, plus Value Added Tax ("VAT") thereon, if payable, at the
     rate applicable at the time of issue by the Company to the Sponsor of a tax
     invoice in respect of the Services.  The Fee shall be paid quarterly in
     advance on the first business day of January, April, July and October in
     each year during the term hereof.
<PAGE>

3.   Effective Period
     ----------------

     This Agreement shall become effective upon its execution, and shall remain
     in effect until either party terminates the Agreement by giving the other
     party ninety (90) days prior written notice of termination.

4.   Relationship of Parties
     -----------------------

     The Company is an independent contractor and is not an agent or employee
     of, and has no authority to bind, the Sponsor by contract or otherwise,
     unless and to the extent expressly authorized in writing by the Board of
     Directors of the Sponsor, whether by grant of power of attorney or
     otherwise.

5.   Confidentiality
     ---------------

     The Sponsor and the Company warrant and undertake that during the term of
     this Agreement and subsequent thereto, it shall maintain confidentiality
     and also be liable for its employees and/or representative and/or persons
     acting on its behalf maintaining absolute confidentiality of all in
     formation, details and data which is in and/or comes to its knowledge
     and/or that of its employees and/or representatives and/or persons acting
     on its behalf directly or indirectly relating to the Services, the Know How
     or any products based on the Know How.  The Sponsor and the Company
     undertake not to convey or disclose (except in connection with the
     fulfillment of its duties under this Agreement) anything in connection with
     the foregoing.  "Confidential Information" shall include, but shall not be
     limited to, confidential or proprietary scientific or technical information
     or data, business plans, trade secrets, or other confidential information
     relating to customers, development programs, costs, marketing, trading,
     investment, sales activities, promotion, credit and financial data,
     manufacturing processes, financing methods, plans or the business and
     affairs of the Sponsor or the Company generally, or of any subsidiary or
     affiliate of the Sponsor or the Company. "Confidential Information" shall
     not include, however, information in the public domain, information
     disclosed to the Sponsor or the Company by a third party entitled to
     disclose it without any obligation of confidentiality, or, information
     already known to the Sponsor or the Company prior to its receipt.

6.   Indemnification.
     ----------------

     The Company agrees to indemnify and hold harmless the Sponsor and its
     respective partners, affiliates, shareholders, directors, officers, agents,
     advisors, representatives, employees, counsel and controlling persons
     within the meaning of the Securities Act of 1933, as amended, (a "Sponsor
     Indemnified Party") from and against any and all direct losses,
     liabilities, claims, damages and expenses whatsoever (and all actions in
     respect thereof) but excluding consequential loss and to reimburse the
     Sponsor Indemnified Party for reasonable legal fees and related expenses as
     incurred (including, but not limited to the costs of giving testimony or
     furnishing documents in response to a subpoena or otherwise, the costs of
     investigating, preparing, pursuing or defending any such action or claim
     whether or not pending or threatened, whether or not resulting in any
     liability, and whether or not the Sponsor or any Sponsor Indemnified Party
     is a party thereto), insofar as such losses, liabilities, claims, damages
     or expenses arise out of, relate to, whether or not resulting in any
     liability, are incurred in connection with or are in any way a result of
     (a) this Agreement, including any modifications or future additions to this
     Agreement, (b)
<PAGE>

     any act by the Company or any Sponsor Indemnified Party taken in connection
     with the services to be provided under this Agreement, (c) the employment
     by the Company of any device, scheme or artifice to defraud, or the
     engaging by the Company in any act, practice or course of business which
     operates or would operate as a fraud or deceit, or any conspiracy with
     respect thereto, in connection with this Agreement; provided, however, that
     the Company will not be liable in any such case if and to the extent that
     any such loss, claim, damage, liability or expense arises out of or is
     based upon the negligence, recklessness or willful misconduct of the
     Sponsor or any Sponsor Indemnified Party.

7.   Amendments: Waivers
     -------------------

     This Agreement may be altered or amended, and any provisions hereof may be
     waived, only upon the written approval of the Sponsor and the Company.

8.   Notices
     -------

     Any notice or other communication given under this Agreement shall be
     deemed to have been given in writing (including telex, telecopy or similar
     teletransmission) addressed as provided below or to the addressee at such
     other address as the addressee shall have specified by notice actually
     received by the addressor), and if either (a) actually delivered in fully
     legible form to such address (evidenced in the case of a telex by receipt
     of the correct answerback) or (b) in the case of a letter, five days shall
     have elapsed after the same shall have been deposited in the post, with
     postage prepaid and registered or certified.

If to the Sponsor, to it at:     c/o Paramount Capital, Inc.
                                 787 Seventh Avenue, 48th floor
                                 New York, New York  10019
                                 Attn: Peter Kash
                                 Tel:  212-554-4340
                                 Fax:  212-554-4355

If to the Company, to it at:     216 Jaffa Road
                                 Sha'arei Ha'ir
                                 Jerusalem, Israel  94383
                                 Attn: Bob Trachtenberg
                                 Tel:  972-2-537-4997
                                 Fax:  972-2-537-5098

9.   Successors
     ----------

     This Agreement shall be binding upon and shall inure to the benefit of the
     parties hereto and their respective heirs, successors and assigns provided,
     however, that neither party may assign this Agreement except to an
     Affiliate that agrees in writing to bound hereby and to assume all of the
     obligations of the assigning party hereunder.  For the purposes hereof, an
     "Affiliate" shall mean any entity that, directly or indirectly through one
     or more intermediaries, controls, or is controlled by, or is under common
     control with, either party hereto.
<PAGE>

10.  Headings
     --------

     The headings in this Agreement are inserted for convenience of reference
     only and shall not be a part of or control or affect the meaning hereof.

11.  Entire Agreement
     ----------------

     This Agreement supersedes any and all oral or written agreements heretofore
     made relating to the subject matter hereof and constitutes the entire
     agreement of the parties relating to the subject matter hereof.

12.  Governing Law
     -------------

     This Agreement shall be governed by and construed in accordance with the
     laws of Israel.

IN WITNESS WHEREOF, each of the undersigned has caused this Agreement to be duly
executed and delivered as an agreement under seal as of the date first above
written.

Lakaro Biopharmaceuticals,  Inc.        B.R.T. Biopharmaceuticals, Ltd.

By: /s/ Bob Trachtenberg                By: /s/ Ira Weinstein
   -----------------------------           ----------------------------
Name: Bob Trachtenberg                  Name: Ira Weinstein
     ---------------------------             --------------------------
Title: Secretary                        Title: CFO
      --------------------------              -------------------------<PAGE>

                                                                   EXHIBIT 10.14

                               FINDER AGREEMENT
                               ----------------

          Pursuant to this Finder Agreement (this "Agreement") entered into
November 19, 1999, (the "Effective Date"), between Lakaro BioPharmaceuticals,
Inc., a company organized under the laws of the State of Delaware, having a
place of business at 216 Jaffa Rd., Sha'arei Ha'ir Jerusalem, Israel 94383 (the
"Company") and Paramount Capital, Inc., having a place of business at 787
Seventh Avenue, 48th Floor, New York, New York 10019 (the "Finder"), the parties
hereto agree:

          1.  In connection with the offering (the "Offering") by the Company of
Units consisting of 1,000 shares of Series A Convertible Preferred Stock, stated
value $100.00 per share (the "Preferred Stock"), the Finder will introduce the
Company to third parties (the "Introduced Parties") with the hope and intent
that the Introduced Parties will purchase Units in the Offering (an
"Investment");

          2.  In the event that during the term of this Agreement, an Introduced
Party makes an Investment in the Company, then the Company shall pay to the
Finder, immediately following the closing of the Investment and the transfer of
the proceeds to the Company, a placement fee in cash equal to five percent (5%)
of such Investment. In addition, the Company, immediately following the closing
of the Investment, shall grant to the Finder and/or its designees, three (3)
year warrants to purchase a number of shares of Common Stock equal to three
percent (3%) of the aggregate number of shares of Common Stock issuable upon
conversion of the Preferred Stock purchased by purchasers of Units in the
Offering at an exercise price equal to $2.91 per share.

          3.  It is understood by the parties that the Finder may utilize the
services of one or more selected dealers that are members of the National
Association of Securities Dealers, Inc., or are located outside the U.S. (a
"Selected Dealer"), locate Introduced Parties. It is further understood by the
parties that any placement fee payable by the Company in connection with such
Introduced Parties shall be payable solely to the Finder. The Finder shall be
solely responsible for any financial arrangements it might make with such
Selected Dealer and the Company shall have no liability whatsoever therefore.

          4.  The Company agrees to indemnify and hold harmless the Finder and
its respective partners, affiliates, shareholders, directors, officers, agents,
advisors, representatives, employees, counsel and controlling persons within the
meaning of the Securities Act of 1933, as amended (the "Securities Act") (a
"Finder Indemnified Party") from and against any and all losses, liabilities,
claims, damages and expenses whatsoever (and all actions in respect thereof),
and to reimburse the Finder Indemnified Party for legal fees and related
expenses as incurred (including, but not limited to the costs of giving
testimony or furnishing documents in response to a subpoena or otherwise, the
costs of investigating, preparing, pursuing or defending any such action or
claim whether or not pending or threatened, whether or not resulting in any
liability, and whether or not the Finder or any Finder Indemnified Party is a
party thereto), insofar as such losses, liabilities, claims, damages or expenses
arise out of, relate to, whether or not resulting in any liability, are in
incurred in connection with or are in any way a result of (i) the engagement of
the Finder pursuant to this Agreement and in connection with the transactions
contemplated by this Agreement and the Confidential Private Placement
Memorandum, the Subscription
<PAGE>

Agreement, the Units and the securities underlying such Units (collectively the
"Offering Documents") (the "Engagement"), including any modifications or future
additions to such Engagement and related activities prior to the date hereof,
(ii) any act by the Finder or any Finder Indemnified Party taken in connection
with the Engagement, (iii) a breach of any representation, warranty, covenant,
or agreement of the Company contained in this Agreement, (iv) the employment by
the Company of any device, scheme or artifice to defraud, or the engaging by the
Company in any act, practice or course of business which operates or would
operate as a fraud or deceit, or any conspiracy with respect thereto, in
connection with the sale of the Units, or (v) any untrue statement or alleged
untrue statement of a material fact contained in any of the Offering Documents
or the omission or alleged omission therefrom of a material fact necessary in
order to make the statements therein, in light of the circumstances under which
they were made, not misleading. Notwithstanding the foregoing, the Company will
not be liable in any such case if and to the extent that any such loss, claim,
damage, liability or expense (A) arises out of or is based upon an untrue
statement or alleged untrue statement or omission or alleged omission made by
any Finder Indemnified Party unless the Finder Indemnified Party's statement or
omission is consistent with information found in the Offering Documents; or (B)
arises out of or is based on information furnished to the Company by the Finder
in writing specifically for use in the Offering Documents.

          5.  Unless sooner terminated by either party at their option at any
time upon ten (10) days written notice and without the payment of any penalty,
this Agreement shall remain in effect for a period of 90 days from the date of
inception, and may be renewed, upon mutual consent, for additional 90 day
periods thereafter. This Agreement shall automatically terminate in the event of
its assignment without the express approval of both parties.

          6.  This Agreement constitutes the entire agreement of the parties
pertaining to the subject matter hereof, and the parties have made no
agreements, representations or warranties relating to the subject matter of this
agreement that are not set forth herein or therein. This Agreement supersedes
and replaces any and all prior agreements or understandings between the parties
hereto, whether written, oral or otherwise.

          7.  The provisions set forth in this Agreement shall be severable. If
any provision contained in this Agreement is found to be invalid, illegal or
unenforceable, such provision shall be limited to the extent possible to render
it enforceable, and the validity of the remaining provisions contained herein
shall not in any way be affected or impaired thereby.

          8.  This Agreement may not be modified, amended or waived in any
manner except by an instrument in writing signed by each of the parties hereto.
The waiver by either party of compliance with any provision of this agreement by
the other party shall not operate or be construed as a waiver of such party of a
provision of this agreement.

          9.  All notices and other communications by either party shall be in
writing and deemed to have been duly given if delivered by hand or sent by
telecopier or facsimile transmission to the parties hereto at the addresses set
forth above, or to such other address as any party hereto specifies to the
other.
<PAGE>

          9.  Neither party may assign its rights or obligations hereunder.

          10. This Agreement shall be governed by and construed in accordance
with the laws of the State of New York, without regard to the conflicts of the
law principles thereof. The parties agree to settle any disputes through binding
arbitration in the city, county and State of New York.

                    IN WITNESS WHEREOF, the parties hereto have caused this
Agreement of Introduction to be executed by their respective duly authorized
representatives as of the day and year written above.

                                   PARAMOUNT CAPITAL, INC.,

                                   By: /s/ Lindsay A. Rosenwald, M.D.
                                      __________________________________
                                   Name: Lindsay A. Rosenwald, M.D.
                                   Title:  Chairman

                                   LAKARO BIOPHARMACEUTICALS, INC.

                                   By: /s/ Ira Weinstein
                                      __________________________________
                                   Name:  Ira Weinstein
                                   Title: Treasurer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}]]